Repertoire Immune Medicines added Eli Lilly to its roster of major partners, securing an up‑front payment and potential milestones that push the alliance value toward roughly $1.9–1.92 billion. The deal targets tolerizing therapies for autoimmune diseases and leverages Repertoire’s Decode platform that maps immune repertoires to therapeutic candidates. Repertoire has accumulated multiple pharma partnerships since 2019; company leadership described the Lilly agreement as a major external validation of its platform and translational output. Terms include development and commercial milestones plus tiered royalties. For the autoimmune field, the deal reflects sustained industry interest in immune‑modulation and tolerization approaches that aim to re‑educate pathogenic immune responses rather than broadly suppress immunity. Repertoire’s platform-centric business model continues to attract strategic collaborations as biopharma firms shore up pipelines in complex immunology indications. Investors will watch program selection, preclinical data, and indication choices; successful translation could accelerate the emergence of antigen‑specific tolerizing medicines as clinical candidates.